2020 Annual Meeting of Stockholders May 5, 2020
2020 Annual Meeting of Stockholders Introductions 2020 Annual Baxter Voting Questions Adjournment and Meeting Meeting Overview Results and Procedures Proposals Answers 2
2020 Annual Meeting of Stockholders May 5, 2020
Baxter’s Board of Directors José (Joe) E. Almeida Thomas T. Stallkamp Thomas F. Chen John D. Forsyth James R. Gavin III, Peter S. Hellman M.D., Ph.D. Michael F. Mahoney Patricia B. Morrison Stephen N. Oesterle, Cathy R. Smith Albert P.L. Stroucken Amy A. Wendell M.D. All Directors up for reelection at the 2020 Annual Meeting 4
Baxter’s Senior Leadership Team Giuseppe Accogli Heather Knight Reaz Rasul SVP and President, Americas GM, U.S. Hospital Products GM, Acute Therapies Laura Angelini Jacqueline (Jackie) Kunzler, Ph.D. Philippe Reale GM, Renal Care SVP and Chief Quality Officer VP, Planning & Fulfillment Alex Blanco Karen Leets David Roman SVP, Global Supply Chain Officer SVP and Treasurer VP, Strategy, Financial Planning and Analysis Wil Boren Paul Martin President, Advanced Surgery SVP and Chief Information Officer James (Jay) Saccaro EVP and Chief Financial Officer Dennis Crowley Sean Martin SVP, Business Development & Licensing SVP and General Counsel Cathy Skala VP, Business Transformation Office Stacey Eisen Jeanne Mason, Ph.D. SVP, Global Communications SVP, Human Resources Brian Stevens SVP, Chief Accounting Officer David Ferguson, Ph.D. Ellen McIntosh and Controller GM, Medication Delivery SVP and Corporate Secretary Clare Trachtman Cristiano Franzi Sumant Ramachandra, M.D., Ph.D. VP, Investor Relations SVP and President, Europe, Middle East, Africa President, Pharmaceuticals, and SVP, Chief Science and Technology Officer Jorge Vasseur Andrew (Andy) Frye GM, Clincal Nutrition SVP and President, Asia Pacific 5
Safe Harbor Statement This presentation includes forward- looking statements concerning Baxter’s financial results, business development activities, ca pital structure, cost savings initiatives, R&D pipeline, including results of clinical trials and planned product launches. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products; product development risks; product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); the impact of global economic conditions (including potential trade wars) and public health crises and epidemics, such as the novel strain of coronavirus (COVID-19), on us and our customers and suppliers, including foreign governments in countries in which we operate; breaches or failures of the company’s information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of the company’s cash flows from operations (which may be negatively impacted by c ollectability concerns as a result of the COVID-19 pandemic or otherwise) and other sources of liquidity to meet its ongoing cash obligations and fund its investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including the FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility or proceedings related to the investigation related to foreign exchange gains and losses; the outcome of pending or future litigation, including the opioid litigation and litigation related to our internal investigation of foreign exchange gains and losses; the impacts of the material weakness identified as a result of the internal investigation and our remediation efforts, including the risk that we may experience additional material weaknesses or other deficiencies; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multi-year capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical and Seprafilm Adhesion Barrier from Sanofi); future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in-licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global, trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filing on Form 10- K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to u pdate its forward-looking statements unless otherwise required by the federal securities laws. 6
2020 Annual Meeting of Stockholders May 5, 2020
2020 Annual Meeting Proposals PROPOSAL PROPOSAL PROPOSAL PROPOSAL PROPOSAL 1 2 3 4 5 Election of Advisory Vote Ratification of Independent Right to Act Directors to Approve Appointment of Board by Written Named Independent Chairman Consent Executive Registered Officer Public Compensation Accounting Firm 8
2020 Annual Meeting of Stockholders May 5, 2020
Advancing our Mission 10
Rising to the Challenge of COVID-19 ► Maximizing production of critical medical products to support increased patient care levels ► Protecting employee health and safety through enhanced infection control procedures ► Actively recruiting up to 2,000 additional permanent and temporary roles globally ► Donating $2M+ to date to global relief partners through The Baxter International Foundation 11
Baxter Profile: A Diversified Global Portfolio 1 2019 Global Revenue ~$3.6B ~$2.8B Renal Care Medication Delivery $1 $11. 1.4B 4B ~$2.2B ~$0.9B Pharmaceuticals Clinical Nutrition Americas 54% ~$0.9B ~$0.5B EMEA 26% Asia Pacific 20% Advanced Surgery Acute Therapies 1 Sales and related figures represent FY 2019; Other sales represent ~$0.5B. 12
Full Year 2019 Financial Snapshot 1 Global Reported Adjusted Adjusted Diluted Free Cash Flow 3 Sales Operating Margin Earnings per Share +5% +140 +14% +4% Operational Growth 2 Basis Points ~$11.4B 4B $3.3 .31 18 18.7% .7% ~$11.1B 1B $1.4 1.4B $1.4 1.4B $2.9 .91 17.3% .3% FY 20 2018 18 FY 20 2019 19 FY 20 2018 18 FY 20 2019 19 FY 20 2018 18 FY 20 2019 19 FY 20 2018 18 FY 20 2019 19 as restated as restated as restated as restated 1 Non-GAAP financial metrics referenced in this slide include operational sales growth, adjusted operating margin, adjusted diluted EPS, and free cash flow. A reconciliation to comparable U.S. GAAP measures is available at www.baxter.com. 2 FY 2019 operational sales growth excludes the impact of foreign currency of approximately 3% and U.S. cyclophosphamide competition of approximately 0%; U.S. GAAP sales growth for the period was 13 approximately 2% compared to FY 2018. 3 Operating cash flows from continuing operations of $2,110 million in 2019 and $2,017 million in 2018 offset by capital expenditures of $696 million in 2019 and $659 million in 2018.
Patient Safety and Quality: Our Top Priority Investing in quality systems and processes Improving key quality metrics Strengthening relationships with global regulators Six FDA warning letters resolved since 2014 Sole remaining open letter: • Ahmedabad, India 15
Best Place to Work: Recognized for Excellence Baxter’s inclusive culture and diverse Baxter drives sustainability throughout its workforce help advance our Mission and operations, and supports increased access fuel innovation. to care, disaster relief, and STEM education, among other efforts. Select recognition highlights: Select recognition highlights: 16
Growth Through Innovation: Expanding our Impact Multiple Avenues to Increase Patient Impact, Accelerate Growth Portfolio Market Enter Innovation Development Adjacencies Executing on pipeline Driving growth through Expanding beyond the opportunities and evidence generation, core to unlock new geographic expansion physician education, and therapies and markets targeted market investments 17
Recommend
More recommend
